Document Classification

Section Type: METHODS

Text: From 1990 to 1996, 162 patients with HD at clinical stages (CS) I-III with bulky disease (mediastinal mass ratio > or = 0. 45 and/or unilateral or bilateral pelvic plus lumboaortic disease ; 86 patients) or CS IV (76 patients) were randomized to receive the same cumulated dose of a CT regimen consisting of epirubicin (240 mg/m (2)), bleomycin (60 mg/m (2)), vinblastine (20 mg/m (2)), vincristine (4 mg/m (2)), cyclophosphamide (4000 mg/m (2)), etoposide (900 mg/m (2)), and methotrexate (180 mg/m (2)) plus methylprednisolone (1500 mg/m (2)) over 12 weeks either every 4 weeks (Arm Y, 79 patients) or every 3 weeks (Arm Z, 83 patients).